A new prognostic model for her2-positive breast cancer


What is HER2-positive breast cancer prognosis?

The survival rate at four years among women with HR+/HER2− is estimated to be 92.5%, followed by HR+/HER2+ at 90.3%, HR−/HER2+ at 82.7%, and HR−/HER2− at 77.0% [1]. The HER2 (human epidermal growth factor receptor 2) oncogene is positive in about 20% of primary invasive breast cancers [2].

Is HER2 a prognostic factor in breast cancer?

HER2 was of prognostic relevance with a HR of 0.67 (OS, 95% CI: 0.48 to 0.92) and 0.79 (PFS, 95% CI: 0.62 to 0.99) indicating that patients with a positive HER2 status had a better prognosis.

What is the new drug for HER2-positive breast cancer?

Enhertu (5.4mg/kg) is approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within …

Is HER2 a prognostic biomarker?

The potential of HER2 as a prognostic biomarker in breast cancer was first reported in 1987, with its amplification associated with reduced time to progression and reduced overall survival.

Can HER2-positive breast cancer be cured?

HER2-positive breast cancer is highly curable because of the availability of these HER2-targeted therapies, so we treat patients fairly aggressively upfront to reduce the risk of them experiencing a stage IV recurrence.

Which is worse HER2-positive or negative breast cancer?

Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. These cancers tend to grow and spread faster than breast cancers that are HER2-negative, but are much more likely to respond to treatment with drugs that target the HER2 protein.

Is HER2 curable 2021?

With recent advances in medicine, it is considered that HER2-positive breast cancer is curable. Targeted therapy is used to cure HER2-positive breast cancer. However, surgery, radiation therapy, chemotherapy and hormonal therapy may also be combined with targeted therapy depending on cancer aggressiveness.

What is the second line treatment for HER2-positive breast cancer?

Lapatinib, a dual tyrosine kinase inhibitor that inhibits the HER2 receptor pathway and the epidermal growth factor receptor (EGFR), is an additional anti-HER2 therapeutic option for second-line, HER2-positive, MBC patients.

What is the 5 year pill for breast cancer?

Tamoxifen. Tamoxifen is usually taken daily in pill form. It’s often used to reduce the risk of cancer recurrence in women who have been treated for early-stage breast cancer. In this situation, it’s typically taken for five to 10 years.

What type of biomarker is HER2?

What is the HER2 biomarker? The HER2 or ERBB2 gene (human epidermal growth factor receptor-2) is in each of the cells in our body and is in the same family as the EGFR gene. The HER2 protein is a receptor on the surface of almost all the cells in our body.

What does HER2 score 2+ mean?

A score of 0 or 1+ means the breast cancer is HER2 negative. A score of 2+ is borderline and a score of 3+ means the breast cancer is HER2 positive. Breast cancers with a borderline result (2+) should be retested using more specialised techniques to determine if they are truly HER2 positive or negative.

What is the ligand for HER2?

HER2 is a transmembrane protein, belonging to the ErbB or epidermal growth factor receptor (EGFR) family1. Structurally it is featured by an N-terminal extracellular ligand binding portion (ECD), a single alpha-helix transmembrane segment (TM), and an intracellular protein tyrosine kinase.

Which has a better prognosis HER2-positive or negative?

HER2-positive breast cancer is more aggressive and more likely to spread than HER2-negative breast cancer. They are also more likely to come back after treatment. This means that HER2-positive breast cancer has a less favourable prognosis than HER2-negative breast cancer. Find out more about HER2 status testing.

Is HER2-positive breast cancer a death sentence?

Current treatment algorithms for invasive HER2-positive disease has transformed the face of a disease with a death sentence to one with prolonged and overall survival benefit.

What is worse triple negative or HER2-positive?

Conclusions: The triple negative subtype has the worst survival regardless of stage. HER2-positive cancers are heterogeneous and not all have poor survival. ER and PR must be considered. ER status appears to influence 5-year survival more than HER2 status.

Is HER2-positive breast cancer metastatic?

About 20% of breast cancers are HER2-positive. They usually grow quicker than other types of cancer. Metastatic HER2-positive breast cancer has spread beyond the breast to other parts of the body.

Leave a Comment